Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT
Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2016
|
| In: |
Bone marrow transplantation
Year: 2015, Jahrgang: 51, Heft: 2, Pages: 212-218 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/bmt.2015.273 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bmt.2015.273 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bmt2015273 
|
| Verfasserangaben: | L. Sellner, A. Boumendil, H. Finel, S. Choquet, G. de Rosa, F. Falzetti, R. Scime, G. Kobbe, F. Ferrara, A. Delmer, H. Sayer, S. Amorim, R. Bouabdallah, J. Finke, G. Salles, I. Yakoub-Agha, E. Faber, E. Nicolas-Virelizier, L. Facchini, D. Vallisa, E. Zuffa, A. Sureda and P. Dreger on behalf of the EBMT Lymphoma Working Party |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1697052177 | ||
| 003 | DE-627 | ||
| 005 | 20230427121958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200504r20162015xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/bmt.2015.273 |2 doi | |
| 035 | |a (DE-627)1697052177 | ||
| 035 | |a (DE-599)KXP1697052177 | ||
| 035 | |a (OCoLC)1341318208 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sellner, Leopold |d 1984- |e VerfasserIn |0 (DE-588)143493825 |0 (DE-627)646576704 |0 (DE-576)337362963 |4 aut | |
| 245 | 1 | 0 | |a Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma |b a retrospective study from the EBMT |c L. Sellner, A. Boumendil, H. Finel, S. Choquet, G. de Rosa, F. Falzetti, R. Scime, G. Kobbe, F. Ferrara, A. Delmer, H. Sayer, S. Amorim, R. Bouabdallah, J. Finke, G. Salles, I. Yakoub-Agha, E. Faber, E. Nicolas-Virelizier, L. Facchini, D. Vallisa, E. Zuffa, A. Sureda and P. Dreger on behalf of the EBMT Lymphoma Working Party |
| 264 | 1 | |c 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published 16 November 2015 | ||
| 500 | |a Gesehen am 05.05.2020 | ||
| 520 | |a Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted. | ||
| 534 | |c 2015 | ||
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 51(2016), 2, Seite 212-218 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma a retrospective study from the EBMT |
| 773 | 1 | 8 | |g volume:51 |g year:2016 |g number:2 |g pages:212-218 |g extent:7 |a Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma a retrospective study from the EBMT |
| 856 | 4 | 0 | |u https://doi.org/10.1038/bmt.2015.273 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/bmt2015273 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200504 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 23 |y j | ||
| 998 | |g 143493825 |a Sellner, Leopold |m 143493825:Sellner, Leopold |d 910000 |d 910100 |e 910000PS143493825 |e 910100PS143493825 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1697052177 |e 3656871167 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Sellner","role":"aut","given":"Leopold","display":"Sellner, Leopold"},{"given":"Peter","role":"aut","display":"Dreger, Peter","family":"Dreger"}],"name":{"displayForm":["L. Sellner, A. Boumendil, H. Finel, S. Choquet, G. de Rosa, F. Falzetti, R. Scime, G. Kobbe, F. Ferrara, A. Delmer, H. Sayer, S. Amorim, R. Bouabdallah, J. Finke, G. Salles, I. Yakoub-Agha, E. Faber, E. Nicolas-Virelizier, L. Facchini, D. Vallisa, E. Zuffa, A. Sureda and P. Dreger on behalf of the EBMT Lymphoma Working Party"]},"id":{"eki":["1697052177"],"doi":["10.1038/bmt.2015.273"]},"physDesc":[{"extent":"7 S."}],"relHost":[{"title":[{"title_sort":"Bone marrow transplantation","title":"Bone marrow transplantation"}],"language":["eng"],"part":{"volume":"51","year":"2016","text":"51(2016), 2, Seite 212-218","extent":"7","pages":"212-218","issue":"2"},"pubHistory":["Nachgewiesen 19.1997 -"],"id":{"zdb":["2004030-1"],"issn":["1476-5365"],"eki":["320433366"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma a retrospective study from the EBMTBone marrow transplantation","note":["Gesehen am 17.01.25"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"1997-","publisher":"Springer Nature ; Macmillan ; Nature Publishing Group","dateIssuedKey":"1997","publisherPlace":"London ; Basingstoke ; London"}],"recId":"320433366"}],"note":["Published 16 November 2015","Gesehen am 05.05.2020"],"recId":"1697052177","origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma","title":"Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma","subtitle":"a retrospective study from the EBMT"}],"language":["eng"]} | ||
| SRT | |a SELLNERLEOTHIOTEPABA2016 | ||